15-Deoxy-Δ
12,14-prostaglandin J
2 (15dPGJ
2), which is a ligand for peroxisome proliferator-activated receptor γ (PPARγ), induced apoptosis of several human tumors including gastric, lung, colon, prostate and breast. However, the role of PPARγ signals in other types of cancer cells such as leukemia, except solid cancer cells, is still unclear. The aim of this study was to evaluate the ability of 15dPGJ
2 on the proliferation of the human T cell leukemia cell line MOLT-4F. 15dPGJ
2 at 5 μM stimulated proliferation in MOLT-4F at 1 to 3 days after incubation. In contrast, 15dPGJ
2 at concentrations of above 10 μM inhibited proliferation. PGD
2, PGJ
2 and Δ
12-PGJ
2 (ΔPGJ
2), which are precursors of 15dPGJ
2, had similarly proliferative effects, whereas they showed anti-proliferative effects at high concentrations. Both SB203580, a p38 mitogen-activated protein kinase (MAPK) inhibitor, and LY294002, a phosphoinositide 3-kinase (PI3K) inhibitor, prevented proliferation accelerated by 15dPGJ
2 and its three precursors in MOLT-4F. In contrast, PD98059, an extracellular signal-related kinase 1/2 inhibitor, did not affect proliferation accelerated by 15dPGJ
2 and its three precursors. Immunoblotting analysis revealed that PGD
2 at 5 μM, PGJ
2 at 5 μM, ΔPGJ
2 at 1 μM and 15dPGJ
2 at 5 μM potentiated the expression of cyclin A, without affecting the expression of Cdk inhibitors including p18, p21, and p27 in MOLT-4F. These results suggest that PGD
2, PGJ
2, ΔPGJ
2 and 15dPGJ
2 may, through the activation of p38 MAPK and/or PI3K, potentiate the expression of cyclin A, leading to acceleration of proliferation in MOLT-4F.
View full abstract